<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00364039</url>
  </required_header>
  <id_info>
    <org_study_id>AV650-012</org_study_id>
    <nct_id>NCT00364039</nct_id>
  </id_info>
  <brief_title>Study to Examine the Safety, Tolerability, and Pharmacokinetics of AV650</brief_title>
  <official_title>A Phase 1 Double-Blind, Placebo-Controlled Single Center Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Dose and Multiple Dose Escalations of AV650 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avigen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avigen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of AV650 in healthy
      subjects given single and multi-doses under fasted and fed conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation and reaction time changes</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Healthy Subjects</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AV650</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoking

          -  Body mass index between 18.5 and 29.9 kg/m2 or body mass index greater than 29.9 kg/m2
             with good to excellent body fat percentage

        Exclusion Criteria:

          -  Known hypersensitivity to lidocaine or non-steroidal anti-inflammatory agents (NSAIDS)

          -  History of clinically significant cardiovascular, pulmonary, endocrine, neurological,
             metabolic, or psychiatric disease

          -  History of HIV or Hepatitis B

          -  History of symptomatic hypotension

          -  History of mental illness, drug addiction, drug abuse or alcoholism

          -  History of cancer

          -  History of inflammatory arthritis (rheumatoid, lupus, psoriatic arthritis)

          -  Current use of immunosuppressive therapy (systemic steroids, cyclosporine) or use of
             nasal or topical steroids

          -  History of gastric or duodenal ulcer disease

          -  History of severe physical injury, direct impact trauma or neurological trauma within
             6 months of Study Day 1

          -  Female subjects who are pregnant or nursing

          -  Have donated blood within 90 days of Study Day -1

          -  Have received an investigational drug within 90 days of Screening

          -  Require regular use of antihistamines, H2 blockers (such as cimetidine, ranitidine),
             TCAs or SSRIs or who have taken these medications witin 14 days of Study Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan A. Bart, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SNBL Clinical Pharmacology Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SNBL Clinical Pharmacology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2006</study_first_submitted>
  <study_first_submitted_qc>August 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <last_update_submitted>February 27, 2007</last_update_submitted>
  <last_update_submitted_qc>February 27, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2007</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

